Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19

10. November 2020 INDIZES USA

Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19 …
(Orginal – Story lesen…)

Tags: dow jones nasdaq s&p 500

You may also like...